Metronomic oral cyclophosphamide in relapsed ovarian cancer.

Pavlina SpiliopoulouSamantha HinsleyIain A McNeishPatricia RoxburghRos Glasspool

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)

Oral metronomic cyclophosphamide showed a clinical benefit in 48% of patients with recurrent ovarian cancer. gBRCA1/2 status can be an independent predictor of response.

Keyphrases

high dose
low dose
acute lymphoblastic leukemia
acute myeloid leukemia
hodgkin lymphoma